Key facts
- Balanced Pharma’s last known valuation is $96.0M (Apr 2024).
- It has raised $8.6M across 3 recorded rounds; the latest was Seed Round ($498K) in Dec 2024.
- Notable investors include Septodont, Verta Life Sciences.
- Balanced Pharma has filed 6 Form Ds with the SEC since 2021, most recently Sep 2025 ($3.2M sold to 1 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Balanced Pharma
Funding rounds
3 roundsAbout Balanced Pharma
Developer of pharmaceutical drugs designed to improve patient comfort and safety in pain management and anesthesia. The company offers dental anesthetics and non-opioid injectable treatments with improved reliability and longer-lasting effects, enabling patients and healthcare providers to achieve safer procedures and more effective pain relief.
- Sector
- Healthcare
- HQ
- Cornelius, NC, United States
- Founded
- 2020
- Employees
- 11
- Website
- balancedpharma.com/
- Ownership
- Privately Held (backing)
Balanced Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Balanced Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Balanced Pharma in its N-PORT filings yet. We sweep new filings monthly.